The management of opioid dependence during pregnancy in rural and remote settings

Naana Afua Jumah MD DPhil, Lisa Graves MD, Meldon Kahan MD MHSc

Nonmedical use of prescription opioids is a growing problem in Canada; in 2011, it had the highest per capita consumption of oxycodone in the world.\(^1\) When a woman with opioid dependence becomes pregnant, adequate management of the addiction is of critical importance for the well-being of both mother and child. Untreated opioid addiction has been associated with risk-taking behaviour, preterm delivery, low birth weight and stillbirth.\(^2,3\) Ideally, antenatal care for women with opioid dependence is accomplished with multidisciplinary care, including treatment of the addiction.\(^4,5\) However, women who live in rural and remote communities may not have access to such care or may have challenges accessing it.\(^6\)

Comprehensive guidelines to manage the care of pregnant women with opioid dependence who live in rural or remote communities do not currently exist. This absence, in addition to a lack of resources, a lack of training in the treatment of addiction in pregnancy and providers’ discomfort with opiate substitution therapy in pregnancy, has contributed to wide variations in the quality of care these women receive.

We evaluate strategies for the treatment of opioid dependency in pregnancy applicable to rural and remote settings, including methadone maintenance therapy, buprenorphine maintenance, slow-release morphine maintenance and opioid detoxification (Box 1).\(^7\) Special consideration is given to members of Canada’s Aboriginal population. Very little literature exists regarding the management of polysubstance use in pregnancy, and a full discussion of the issue is beyond the scope of this review.

What is the recommended treatment for opioid dependence during pregnancy?

The management of opioid dependence in pregnancy in rural and remote settings requires special consideration (Boxes 2 and 3).

Methadone maintenance therapy is the gold standard for treating opioid dependence in pregnancy.\(^12,13\) Numerous studies have shown that, in pregnant women who use heroin, methadone is associated with more visits for antenatal care, longer gestations, higher birth weights, lower rates of HIV infection, higher rates of infant discharge home in care of the mother and lower rates of relapse compared to nonmedical use of prescription opioids during pregnancy is becoming more common, and members of Canada’s Aboriginal population are disproportionately affected.

• Methadone maintenance therapy has logistic limitations in rural and remote settings, but buprenorphine and slow-release morphine maintenance therapies are feasible alternatives.

• Opioid detoxification in pregnancy is associated with high rates of relapse and should only be offered if a comprehensive rehabilitation program is available.

• Treatment of opioid dependence and rehabilitation services should be provided to all women during pregnancy and the postpartum period.

Key points
Methadone has important logistical limitations that prohibit its use in resource-limited locations. Methadone can only be prescribed by physicians who hold a special license. Because of the high risk of overdose at the start of treatment, methadone must be dispensed daily and ingested under the observation of a licensed pharmacist at a registered pharmacy. Because many rural and remote communities are unable to provide this service, methadone is not offered.

What are the alternatives to methadone maintenance therapy?

Observational studies have shown buprenorphine maintenance therapy to be a safe and efficacious alternative to methadone for the treatment of opioid dependence in pregnant women. Recent randomized controlled trials have shown that buprenorphine and methadone cause similar reductions in maternal opioid use and similar birth and neonatal outcomes, and that buprenorphine is associated with decreased severity of symptoms of neonatal abstinence syndrome. A case series describing 10 women who took buprenorphine plus naloxone maintenance therapy showed outcomes similar to those of buprenorphine alone.

Buprenorphine is a partial μ-opioid receptor agonist that has a lower risk of fatal overdose than full μ-opioid agonists such as methadone. Buprenorphine may precipitate withdrawal if caution is not exercised at the start of treatment. The drug may also incompletely treat withdrawal symptoms, putting patients at risk for ongoing use of illicit drugs to manage their symptoms. Furthermore, buprenorphine may be less effective than methadone at retaining patients in treatment if they used opioids intravenously.

Unlike methadone, Health Canada does not require an exemption to prescribe buprenorphine; however, outside of Ontario and Quebec, public funding of buprenorphine is restricted to physicians with a methadone license. The buprenorphine formulation now includes naloxone, which is intended to deter misuse. Addiction literature often cites naloxone as a possible teratogen and warns against its use in pregnancy. However, the United States Food and Drug Administration classifies naloxone as a pregnancy category B drug, meaning that there have been no reports of teratogenicity in humans or animals. The greater concern in pregnant women with opioid dependence is naloxone’s ability to precipitate withdrawal if taken intravenously or intranasally. Naloxone has minimal buccal or sublingual absorption. As previously described, acute opioid withdrawal is associated with morbidity for both the woman and her fetus.

What if methadone and buprenorphine are not available?

Slow-release morphine maintenance therapy has been proposed as an alternative to methadone when the latter is not available. In resource-limited areas, slow-release morphine may be more accessible because a special license to prescribe it is not required, and it is readily available in pharmacies. Accessibility is also the most notable drawback of morphine because it is more easily acquired and diverted than methadone. In addition, morphine is more easily injected than methadone, and it cannot be distinguished from heroin in a urine screening, limiting the usefulness of urine screens during treatment.

We identified one prospective, randomized trial showing reductions in maternal opioid use and similar neonatal outcomes when pregnant women were randomized to receive methadone or slow-release morphine. Given these results and the logistical ease of providing slow-release morphine as compared to methadone, we recommend slow-release morphine as a first-line alternative to methadone for opioid-dependent pregnant women who are unwilling or unable to use methadone.
A study that compared methadone with slow-release morphine maintenance that included 24 women in each arm. No difference in neonatal outcomes, including neonatal abstinence syndrome, was seen between the two groups. Mothers taking slow-release morphine had a significant decrease in the use of benzodiazepines and other opioids. Two smaller observational studies showed that pregnant women taking slow-release morphine were significantly less likely to use benzodiazepines or additional opioids while undergoing treatment. A hypothesized advantage of morphine is a decreased duration of neonatal abstinence syndrome owing to its shorter half-life compared with methadone.

**Is neonatal abstinence syndrome a problem?**

Neonatal abstinence syndrome has not been associated with long-term neurodevelopmental harms in children, whereas ongoing maternal substance use is associated with poor developmental outcomes in children. The syndrome is time-limited as the infant withdraws from in utero exposure to an opioid. No association has been found between a mother’s methadone dose and the severity of symptoms of neonatal abstinence syndrome. Furthermore, pharmacodynamic studies show that escalations in dose and the severity of symptoms of neonatal abstinence syndrome increase as pregnancy progresses owing to changes in methadone metabolism.

**Is there a role for detoxification in pregnancy?**

An early observational study showed similar outcomes among pregnant women who used heroin and had undergone medical detoxification compared with a control group consisting of pregnant women with no opioid dependency. However, medical detoxification was deemed a failure because of its inability to provide durable abstinence. This study was contrasted by two early case reports documenting adverse pregnancy outcomes in women undergoing acute heroin withdrawal rather than medically managed detoxification. This contrasting evidence led to a resurgence of interest in medical detoxification in pregnancy in the 1990s. Complete opioid detoxification was recommended in a 2002 publication, with the aim of eliminating neonatal abstinence syndrome.

Among the five retrospective case series involving women with heroin addiction, there is no consensus on the rate of methadone taper or the superiority of inpatient versus outpatient detoxification (Box 4). Although the literature cites concerns for increased rates of miscarriage with detoxification during the first trimester and increased rates of preterm labour with detoxification during the third trimester, this effect was not shown. Neonatal outcomes, when reported, were inconsistent. In addition, maternal heroin use postpartum and ongoing addiction treatment postpartum were not reported.

We recommend that acute detoxification in pregnancy should be abandoned, given the evidence, with the exception of women who decline opioid substitution therapy. In this circumstance, a woman should be given the opportunity to transfer into an opioid substitution program at any time if she elects to do so or if she is unable to successfully taper off of opioids. Postpartum rehabilitation services must be provided for all women, particularly those who have chosen abstinence.

**How does opioid dependence in pregnancy affect rural or remote Aboriginal populations?**

Canada’s Aboriginal communities are predominately in rural and remote areas and are disproportionately affected by opioid dependence, with rates between 50% and 80%. Nonmedical use of prescription opioids is more common than heroin use, and the route of exposure is more often oral than intravenous. A 2012 descriptive report from Northwestern Ontario questioned whether the benefits seen with methadone in people who use heroin are applicable in remote Aboriginal communities where women engage in binge use of prescription opioids owing to

---

**Box 3: Resources for clinicians**

intermittent drug availability rather than daily use of heroin. No evidence supports or refutes this claim.

A prevalence study involving First Nations women receiving antenatal care in Sioux Lookout, Ontario, showed that opioid use increased from 8% to 18% during the 18-month study. Neonatal abstinence syndrome in infants exposed to opioids was 30% overall and 66% among infants born to women who used opioids daily. Of the children affected, only 7% required pharmacologic treatment, whereas the remainder received supportive care. Pilot studies are in progress in First Nations communities in Northwestern Ontario to investigate community-based provision of buprenorphine maintenance therapy where methadone is not available and to provide locally trained maternal support workers for women with opioid dependence during pregnancy and continuing until the child reaches 3 years of age.

**Conclusion**

Although methadone is the gold standard for treatment of opioid dependency in pregnancy, methadone therapy is often not feasible in rural and remote settings. Proposed alternatives to methadone, such as opioid detoxification and slow-release morphine substitution, have limited evidence to support their use in pregnancy. Stronger evidence exists to support buprenorphine maintenance therapy.

A fundamental flaw of each study is the choice of birth as an end point. This enables reporting of nominal success rates in terms of abstinence at the time of delivery and neonatal abstinence syndrome. However, the true end

---

**Box 4: Summary of retrospective case series describing methadone detoxification in pregnancy**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Protocol</th>
<th>Outcomes at delivery</th>
</tr>
</thead>
</table>
| Maas et al. 1990 | *Outpatient detoxification lasting 2–8 wk*  
> *Individualized taper of 0.2–1 mg of methadone daily*  
> *Abstinence: 17/58*  
> *MMT taper: 8/58*  
> *MMT taper with illicit drug use: 32/58*  
> *Lost to follow-up: 1/58* | *Fewer NAS symptoms, lower PTD rate, higher body weight, longer pregnancies among women who abstained, followed by women who underwent MMT, compared with women who continued to use heroin* |
| Dashe et al. 1998 | Stabilization  
> *Clonidine: mild withdrawal*  
> *Methadone: moderate to severe withdrawal*  
> *Taper: No more than 20% every 3 d*  
> *Abstinence: 59%*  
> *MMT: 12%*  
> *Illicit drug use: 29%* | *NAS: 44% of infants showed symptoms, 15% required treatment*  
> *PTD: no deliveries before 36 wk*  
> *Stillbirth: none* |
| Luty et al. 2003 | *21-d inpatient methadone taper*  
> *51 women lost to follow-up*  
> *Complete records for 24 women and 22 infants*  
> *Abstinence: 1/24*  
> *MMT and opiate use: not documented*  
> *Rehabilitation program postpartum: none* | *NAS: Not documented*  
> *PTD: 7/22 infants for whom records were available*  
> *Stillbirth: None* |
| Jones et al. 2008 | *3-d methadone taper (n = 75)*  
> *Day 1, 20 mg; day 2, 10 mg; day 3, 10 mg*  
> *7-d methadone taper (n = 48)*  
> *Day 1, 30 mg; dose reduced by 5 mg each day thereafter*  
> *Abstinence: 47% (3-d taper) and 43% (7-d taper)*  
> *MMT: 11% (3-d taper) and 42% (7-d taper)*  
> *Illicit drug use: 53% (3-d taper) and 57% (7-d taper) vs. 23% in control group receiving MMT* | *No difference between case and control groups for NAS, low birth weight or APGAR scores* |
| Stewart et al. 2013 | Stabilization  
> *Methadone dose based on history of use and titrated up based on withdrawal symptoms*  
> *Abstinence: 56%*  
> *MMT: 18%*  
> *Illicit drug use: 44%* | *NAS: Lower Finnegan scores, shorter stays in hospital and less treatment*  
> *PTD: No difference*  
> *Stillbirth: 2 (mothers were actively using heroin)* |

Note: APGAR = appearance, pulse, grimace, activity, respiration; MMT = methadone maintenance therapy; NAS = neonatal abstinence syndrome; PTD = preterm delivery.
point is either sustained abstinence or stable opioid substitution therapy that would enable the new mother to parent her child. In this regard, the literature suggests that postpartum treatment is generally not provided to women in rural and remote communities, which contributes to high rates of relapse and apprehension of infants into custody.\(^2,13,44\)

Despite knowledge of harm and rising rates of opioid dependence in pregnancy, there is a paucity of high-quality evidence in this area and none that specifically addresses the needs of rural and remote communities or Aboriginal communities, polysubstance use or postpartum management. There is an overwhelming need for training in opioid dependence therapy, regulatory changes to ensure pregnant women have access to appropriate medications and greater access to comprehensive treatment both during pregnancy and postpartum in rural and remote settings.

References


**Affiliations:** Thunder Bay Regional Research Institute, Thunder Bay, Ont., and Department of Obstetrics and Gynaecology (Jumah), University of Toronto, Toronto, Ont.; Department of Family Medicine (Graves), Northern Ontario School of Medicine, Sudbury, Ont.; Department of Family and Community Medicine, University of Toronto, and Substance Use Service, Women’s College Hospital (Kahan), Toronto, Ont.

**Contributors:** Naana Afua Jumah was responsible for the primary literature review, the analysis and interpretation of data and the drafting and revising of the article. Lisa Graves and Meldon Kahan contributed to the analysis and interpretation of the data and revised the article for important intellectual content. All of the authors approved the final version submitted for publication and agree to act as guarantors of the work.